FIELD: biotechnology.
SUBSTANCE: vaccine based on virus-like particles for the prevention of COVID-19 is described, including: a mixture of recombinant virus-like particles containing S protein on the surface, variants 19A, Alpha, Delta, Omicron SARS-CoV-2 synthesized in the baculovirus expression system, - 20, 30, 40, 50, 60, 70 or 80 micrograms; potassium dihydrogen phosphate - 0.29 mg; disodium hydrophosphate - 0.30 mg; sodium chloride - 1.84 mg; potassium chloride - 0.04 mg; calcium chloride - 0.02 mg; tris(hydroxymethyl)aminomethane HCl - 0.03 mg; squalene–based adjuvant - 0.25 ml; thiomersal - 4.00 mcg; water for injection - up to 0.5 ml. Also described a method for the prevention of COVID-19, including the administration of the specified vaccine intramuscularly twice with an interval of 21 days between injections.
EFFECT: group of inventions provides for the creation of a vaccine with immunogenicity sufficient to form an immune response against COVID-19, the ability to induce a humoral and cellular immune response, and stimulate the protective immunity of mucous membranes.
2 cl, 5 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VIRUS-LIKE PARTICLES (VLP) VACCINE FOR PREVENTION OF COVID-19 FOR INTRANASAL USE | 2024 |
|
RU2828323C1 |
| VIRUS-LIKE CHIMERIC PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 CONTAINING CORONAVIRUS AND ROTAVIRUS PROTEINS | 2022 |
|
RU2779810C1 |
| HUMAN ROTAVIRUS INFECTION VACCINE BASED ON ROTAVIRUS VIRUS-LIKE PARTICLES | 2024 |
|
RU2829862C1 |
| RECOMBINANT VIRUS-LIKE PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 | 2021 |
|
RU2769224C1 |
| IMMUNOBIOLOGICAL AGENT BASED ON VIRUS-LIKE PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST INFECTION CAUSED BY HUMAN ROTAVIRUS A | 2022 |
|
RU2795055C1 |
| CONJUGATE OF THE RECEPTOR-BINDING DOMAIN (RBD) PROTEIN OF SARS-CoV-2 SURFACE GLYCOPROTEIN S WITH POLYGLUCIN-SPERMIDINE (PGS) POLYMER AND VACCINE COMPLEX AGAINST CORONAVIRUS INFECTION COVID-19 BASED ON THE SPECIFIED CONJUGATE AND PLASMID DNA PVAX-RBD | 2022 |
|
RU2781294C1 |
| HYBRID GENE CONSISTING OF THE RBD RECEPTOR OF THE SURFACE PROTEIN S OF SARS-CoV-2 CORONAVIRUS, S14P5 AND S21P2 EPITOPES, Fc FRAGMENT, FOR OBTAINING A RECOMBINANT ANTIGEN AND ITS USE AS PART OF A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION | 2022 |
|
RU2795160C1 |
| AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LIQUID FORM (VERSIONS) | 2021 |
|
RU2743963C1 |
| AGENT FOR SPECIFIC PREVENTION OF COVID-19 FOR CARNIVORES | 2021 |
|
RU2768749C1 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
